Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t
How this was made
The 30-second read
Why it matters
The Q3 filing provides the first detailed efficacy readout of the onvansertib + FOLFIRI/bev regimen and confirms sufficient cash to fund a planned Phase 3 trial.
Market read
New trial data and cash runway may influence CRDF valuation and peer biotech stocks.
What to watch
Potential regulatory delays and competition from other PLK1 inhibitors could dampen upside.
Background
Cardiff Oncology is a clinical‑stage biotech focused on PLK1 inhibition for RAS‑mutated cancers.
Ticker impact
Cardiff Oncology filed its 8‑K reporting Q3 2026 results, including ongoing Phase 2 trial data and cash runway details.
potential modest upside as investors price in trial progress and cash runway
Trial data shows median PFS not reached versus 11‑month historical control, indicating efficacy; cash runway to Q3 2027 reduces near‑term financing risk, but no regulatory milestone yet.
Market effects
Phase 2 oncology data may lift peer RAS‑mutated cancer biotech stocks.
Limited to US biotech sector; no broader regional effect.
Modest, confined to specialty oncology investors.
Counterpoint
Trial data still early; investors may overvalue potential without Phase 3 readout.
Key entities
- companyCardiff Oncology, Inc.
Clinical‑stage biotech developing onvansertib.
- partnerNerviano Medical Sciences S.r.l.
Licensor of onvansertib rights.
